Items Tagged ‘Sutent’

January 5, 2018

FDA Grants Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma

By

CancerConnect News: The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy.  The FDA previously approved Cabometyx in 2016 for treatment of […]

View full entry

Tags: Cabometyx, cabozantinib, kidney cancer, News, Renal Cancer, renal cell carcinoma, Sutent